HUE066594T2 - Anti-GARP antitest - Google Patents
Anti-GARP antitestInfo
- Publication number
- HUE066594T2 HUE066594T2 HUE16848676A HUE16848676A HUE066594T2 HU E066594 T2 HUE066594 T2 HU E066594T2 HU E16848676 A HUE16848676 A HU E16848676A HU E16848676 A HUE16848676 A HU E16848676A HU E066594 T2 HUE066594 T2 HU E066594T2
- Authority
- HU
- Hungary
- Prior art keywords
- garp antibody
- garp
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015187488 | 2015-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE066594T2 true HUE066594T2 (hu) | 2024-08-28 |
Family
ID=58386752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16848676A HUE066594T2 (hu) | 2015-09-24 | 2016-09-23 | Anti-GARP antitest |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US11046780B2 (enExample) |
| EP (3) | EP3354729B1 (enExample) |
| JP (5) | JP6878283B2 (enExample) |
| KR (2) | KR20250037587A (enExample) |
| CN (3) | CN108026521B (enExample) |
| AU (3) | AU2016325858B2 (enExample) |
| BR (1) | BR112018005777A2 (enExample) |
| CA (1) | CA2999819A1 (enExample) |
| CO (1) | CO2018003542A2 (enExample) |
| DK (1) | DK3354729T5 (enExample) |
| ES (1) | ES2978126T3 (enExample) |
| FI (1) | FI3354729T3 (enExample) |
| HR (1) | HRP20240495T1 (enExample) |
| HU (1) | HUE066594T2 (enExample) |
| IL (3) | IL258322B2 (enExample) |
| LT (1) | LT3354729T (enExample) |
| MX (2) | MX2018003594A (enExample) |
| MY (1) | MY194586A (enExample) |
| PH (1) | PH12018500642A1 (enExample) |
| PL (1) | PL3354729T3 (enExample) |
| PT (1) | PT3354729T (enExample) |
| RS (1) | RS65415B1 (enExample) |
| RU (2) | RU2769379C2 (enExample) |
| SG (2) | SG11201802352VA (enExample) |
| SI (1) | SI3354729T1 (enExample) |
| SM (1) | SMT202400160T1 (enExample) |
| TW (2) | TWI751979B (enExample) |
| WO (1) | WO2017051888A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201800889SA (en) | 2013-08-01 | 2018-03-28 | Univ Catholique Louvain | Anti-garp protein and uses thereof |
| KR20190080992A (ko) | 2015-05-21 | 2019-07-08 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| AU2016325858B2 (en) | 2015-09-24 | 2022-05-26 | Daiichi Sankyo Company, Limited | Anti-GARP antibody |
| US11046782B2 (en) * | 2016-03-30 | 2021-06-29 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
| SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| PL3694529T3 (pl) | 2017-10-13 | 2024-12-16 | Harpoon Therapeutics, Inc. | Trójswoiste białka i sposoby zastosowania |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| KR102860409B1 (ko) | 2017-12-12 | 2025-09-16 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체 및 관련 방법 |
| MY208015A (en) * | 2018-05-31 | 2025-04-07 | Univ Tokyo | Anti-human tlr7 antibody |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN113286817B (zh) | 2018-09-25 | 2025-01-28 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US20240190961A1 (en) * | 2019-10-25 | 2024-06-13 | Daiichi Sankyo Company, Limited | Combination of anti-garp antibody and immunomodulator |
| US20230192867A1 (en) * | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| AU2021391054A1 (en) * | 2020-12-02 | 2023-06-22 | Shanghai Henlius Biotech, Inc. | ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| AU2022208361A1 (en) | 2021-01-13 | 2023-07-27 | Daiichi Sankyo Company, Limited | Anti-dll3 antibody-drug conjugate |
| MX2023008261A (es) | 2021-01-13 | 2023-09-12 | Memorial Sloan Kettering Cancer Center | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. |
| BR112023014319A2 (pt) * | 2021-01-18 | 2023-09-26 | Jiangxi Jemincare Group Co Ltd | Anticorpo contra a proteína garp e aplicação do mesmo |
| AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| JP2025526336A (ja) | 2022-07-22 | 2025-08-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ |
| CN120418289A (zh) | 2022-12-14 | 2025-08-01 | 安斯泰来制药欧洲有限公司 | 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法 |
| CN121127500A (zh) | 2023-04-07 | 2025-12-12 | 达科纳治疗有限公司 | 针对激活素a受体样1型(alk1)的双特异性激动性抗体 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| DE69333823T2 (de) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| JPH09506508A (ja) | 1993-12-03 | 1997-06-30 | メディカル リサーチ カウンシル | 組換え結合タンパク質およびペプチド |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| JP4169478B2 (ja) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用 |
| AU3672800A (en) | 1999-04-09 | 2000-11-14 | Kyowa Hakko Kogyo Co. Ltd. | Method for controlling the activity of immunologically functional molecule |
| CN1333274A (zh) * | 2000-07-07 | 2002-01-30 | 上海博德基因开发有限公司 | 一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸 |
| HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
| IL161686A0 (en) | 2001-11-01 | 2004-09-27 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| PT1583830E (pt) | 2003-01-07 | 2006-11-30 | Symphogen As | Método para produzir proteínas policlonais recombinantes |
| WO2006089678A2 (en) | 2005-02-22 | 2006-08-31 | Bioinvent International Ab | Antibodies and peptides binding to hiv tat, and uses thereof |
| US8815526B2 (en) | 2005-03-31 | 2014-08-26 | Case Western Reserve University | Methods and reagents for identifying/isolating T regulatory (Treg) cells and for treating individuals |
| US20110086367A1 (en) | 2006-04-03 | 2011-04-14 | Medizinische Hochschule Hannover | Pharmaceuticals for influencing the reaction of the human immune system |
| JP2010512791A (ja) | 2006-12-22 | 2010-04-30 | シェーリング コーポレイション | Ｃｄ２００ｒに対する抗体 |
| CA2711806A1 (en) | 2008-01-11 | 2009-07-16 | Morphosys Ag | Display vectors and methods and uses thereof |
| US8114968B2 (en) | 2008-03-03 | 2012-02-14 | Dyax Corp. | Metalloproteinase-12 specific monoclonal antibody |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| WO2010055950A1 (ja) | 2008-11-17 | 2010-05-20 | 財団法人ヒューマンサイエンス振興財団 | 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療 |
| TWI480050B (zh) | 2009-02-10 | 2015-04-11 | Daiichi Sankyo Co Ltd | 抗－ｍｓｔ１ｒ抗體及其用途 |
| TWI526223B (zh) | 2009-05-11 | 2016-03-21 | Ｕ３製藥有限責任公司 | 人化ａｘｌ抗體類 |
| MX362513B (es) | 2010-03-23 | 2019-01-22 | Intrexon Corp | Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos. |
| RU2644678C1 (ru) | 2010-10-29 | 2018-02-13 | Дайити Санкио Компани, Лимитед | Новое антитело против dr5 |
| US8440797B2 (en) | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
| AU2012248470B2 (en) * | 2011-04-25 | 2016-10-27 | Daiichi Sankyo Company, Limited | Anti-B7-H3 antibody |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| KR20140138215A (ko) | 2012-03-30 | 2014-12-03 | 다이이찌 산쿄 가부시키가이샤 | 신규 항 Ｓｉｇｌｅｃ-15 항체 |
| SG11201406422TA (en) | 2012-04-09 | 2014-11-27 | Daiichi Sankyo Co Ltd | Anti-fgfr2 antibody |
| MY166821A (en) | 2012-04-27 | 2018-07-23 | Daiichi Sankyo Co Ltd | Anti-robo4-antibody |
| JP2014141434A (ja) * | 2013-01-24 | 2014-08-07 | Daiichi Sankyo Co Ltd | 抗ｒｏｂｏ４抗体 |
| DK3421486T5 (da) * | 2012-06-22 | 2024-09-16 | The Trustees Of Darthmouth College | Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser |
| ES2782248T3 (es) | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila |
| US20150284455A1 (en) * | 2012-11-06 | 2015-10-08 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
| SG10201800889SA (en) * | 2013-08-01 | 2018-03-28 | Univ Catholique Louvain | Anti-garp protein and uses thereof |
| EP2832747A1 (en) * | 2013-08-01 | 2015-02-04 | Université Catholique de Louvain | Anti-GARP protein and uses thereof |
| EP3253796A1 (en) | 2015-02-03 | 2017-12-13 | Université Catholique de Louvain | Anti-garp protein and uses thereof |
| AU2016325858B2 (en) * | 2015-09-24 | 2022-05-26 | Daiichi Sankyo Company, Limited | Anti-GARP antibody |
| US11046782B2 (en) * | 2016-03-30 | 2021-06-29 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination |
-
2016
- 2016-09-23 AU AU2016325858A patent/AU2016325858B2/en active Active
- 2016-09-23 IL IL258322A patent/IL258322B2/en unknown
- 2016-09-23 HU HUE16848676A patent/HUE066594T2/hu unknown
- 2016-09-23 KR KR1020257006887A patent/KR20250037587A/ko active Pending
- 2016-09-23 TW TW105130782A patent/TWI751979B/zh active
- 2016-09-23 CA CA2999819A patent/CA2999819A1/en active Pending
- 2016-09-23 HR HRP20240495TT patent/HRP20240495T1/hr unknown
- 2016-09-23 ES ES16848676T patent/ES2978126T3/es active Active
- 2016-09-23 CN CN201680056149.9A patent/CN108026521B/zh active Active
- 2016-09-23 KR KR1020187008255A patent/KR102776730B1/ko active Active
- 2016-09-23 MX MX2018003594A patent/MX2018003594A/es unknown
- 2016-09-23 IL IL288784A patent/IL288784B2/en unknown
- 2016-09-23 EP EP16848676.9A patent/EP3354729B1/en active Active
- 2016-09-23 RU RU2018114904A patent/RU2769379C2/ru active
- 2016-09-23 SI SI201631810T patent/SI3354729T1/sl unknown
- 2016-09-23 IL IL302932A patent/IL302932A/en unknown
- 2016-09-23 SG SG11201802352VA patent/SG11201802352VA/en unknown
- 2016-09-23 RS RS20240428A patent/RS65415B1/sr unknown
- 2016-09-23 LT LTEPPCT/JP2016/078067T patent/LT3354729T/lt unknown
- 2016-09-23 EP EP19218146.9A patent/EP3660051A1/en active Pending
- 2016-09-23 FI FIEP16848676.9T patent/FI3354729T3/fi active
- 2016-09-23 CN CN202211442176.3A patent/CN115869398B/zh active Active
- 2016-09-23 SG SG10201912570UA patent/SG10201912570UA/en unknown
- 2016-09-23 US US15/761,045 patent/US11046780B2/en active Active
- 2016-09-23 SM SM20240160T patent/SMT202400160T1/it unknown
- 2016-09-23 CN CN201911407390.3A patent/CN110922481A/zh active Pending
- 2016-09-23 PT PT168486769T patent/PT3354729T/pt unknown
- 2016-09-23 PL PL16848676.9T patent/PL3354729T3/pl unknown
- 2016-09-23 RU RU2022108079A patent/RU2022108079A/ru unknown
- 2016-09-23 DK DK16848676.9T patent/DK3354729T5/da active
- 2016-09-23 WO PCT/JP2016/078067 patent/WO2017051888A1/ja not_active Ceased
- 2016-09-23 EP EP24157462.3A patent/EP4349997A3/en active Pending
- 2016-09-23 TW TW110146254A patent/TWI836305B/zh active
- 2016-09-23 MY MYPI2018000433A patent/MY194586A/en unknown
- 2016-09-23 BR BR112018005777-0A patent/BR112018005777A2/pt active Search and Examination
- 2016-09-23 JP JP2017540925A patent/JP6878283B2/ja active Active
-
2018
- 2018-03-22 MX MX2023003470A patent/MX2023003470A/es unknown
- 2018-03-22 PH PH12018500642A patent/PH12018500642A1/en unknown
- 2018-04-03 CO CONC2018/0003542A patent/CO2018003542A2/es unknown
- 2018-07-24 US US16/044,196 patent/US10550198B2/en active Active
-
2020
- 2020-02-06 AU AU2020200866A patent/AU2020200866B2/en active Active
- 2020-09-29 JP JP2020164126A patent/JP6868739B2/ja active Active
-
2021
- 2021-04-28 JP JP2021075739A patent/JP7137657B2/ja active Active
- 2021-06-28 US US17/361,137 patent/US12006372B2/en active Active
-
2022
- 2022-09-02 JP JP2022140119A patent/JP2022169801A/ja active Pending
- 2022-09-14 AU AU2022231706A patent/AU2022231706B2/en active Active
-
2024
- 2024-04-30 US US18/650,725 patent/US20240360245A1/en active Pending
- 2024-12-25 JP JP2024228911A patent/JP2025036561A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259048A (en) | Antibodies against ror-1 | |
| SG10201912570UA (en) | Anti-garp antibody | |
| SG10201913864RA (en) | Anti-LAG-3 Antibodies | |
| IL253633B (en) | Anti-transthyretin antibodies | |
| GB201521391D0 (en) | Antibodies | |
| SG11201706126WA (en) | Anti-transthyretin antibodies | |
| SG10202010735PA (en) | Tau-binding antibodies | |
| GB201521382D0 (en) | Antibodies | |
| IL255323A0 (en) | Anti-fcrn antibodies | |
| IL268889A (en) | Anti-EPHA4 antibody | |
| SG11201706125QA (en) | Anti-transthyretin antibodies | |
| GB201515351D0 (en) | Antibody | |
| GB201600871D0 (en) | Antibody | |
| SI3336185T1 (sl) | Protitelo | |
| IL257368A (en) | antibody | |
| GB201509907D0 (en) | Antibodies | |
| GB201522394D0 (en) | Antibodies | |
| IL284022A (en) | Anti-transthyretin antibodies | |
| GB201513447D0 (en) | Antibody | |
| GB201518728D0 (en) | Antibodies | |
| GB201515572D0 (en) | Anti-LAG-3 antibodies | |
| GB201515570D0 (en) | Anti-LAG-3 antibodies | |
| GB201514425D0 (en) | Antibodies | |
| GB201508444D0 (en) | Antibodies | |
| GB201508437D0 (en) | Antibodies |